TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Abbisko Cayman Limited ( (HK:2256) ) is now available.
Abbisko Cayman Limited announced that all resolutions proposed at its Annual General Meeting on June 18, 2025, were approved by shareholders. Key resolutions included the re-election of directors, approval of financial statements, authorization for the board to fix directors’ remuneration, re-appointment of auditors, and granting of mandates for share issuance and repurchase. These approvals are expected to support the company’s strategic and operational flexibility, enhancing its market positioning and shareholder value.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands, operating with limited liability. It is listed on the Stock Exchange of Hong Kong, focusing on the pharmaceutical industry, particularly in drug discovery and development.
Average Trading Volume: 5,860,635
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.37B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.